Original language | English |
---|---|
Pages (from-to) | 9005-9005 |
Number of pages | 1 |
Journal | Journal of Clinical Oncology |
Volume | 31 |
Issue number | 15 supplement |
DOIs | |
Publication status | Published - 20 May 2013 |
Event | Annual Meeting of the American Society of Clinical Oncology (ASCO) - Chicago, United States Duration: 31 May 2013 → 4 Jun 2013 |
BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)
Jeffrey Alan Sosman, Adil Daud, Jeffrey S. Weber, Kevin Kim, Richard Kefford, Keith Flaherty, Jeffrey R. Infante, Omid Hamid, Jonathan S. Cebon, Lynn Mara Schuchter, Robert R. McWilliams, Mario Sznol, William Howard Sharfman, Alain Patrick Algazi, Karl D. Lewis, Shonda M. Little, Peng Sun, Georgina Long, Kiran Patel, Rene Gonzalez
Research output: Contribution to journal › Meeting abstract